FrancophonIA/ELRC3.0 huggingface dataset:
English: Remove the plastic flip-top cap from the Respreeza vial.
Slovenian: Odstranite plastično zunanjo zaščitno zaporko z viale zdravila Respreeza.
English: The recommended dose of 60 mg / kg bw will take approximately 15 minutes to infuse.
Slovenian: Infundiranje priporočenega odmerka 60 mg/kg telesne mase traja približno 15 minut.
English: Follow the steps provided below for the preparation and reconstitution of Respreeza:
Slovenian: Za pripravo in rekonstitucijo zdravila Respreeza sledite spodnjim navodilom:
English: Since alpha1-proteinase inhibitor is an endogenous human protein, it is considered unlikely that Respreeza will cause harm to the foetus when given at recommended doses.
Slovenian: Ker je zaviralec alfa1-proteinaze endogena človeška beljakovina, ni verjetno, da bi zdravilo Respreeza škodovalo plodu, če se daje v priporočenih odmerkih.
English: One-hundred forty subjects (76 Respreeza-treated subjects and 64 subjects treated with placebo in the RAPID Study) continued into the RAPID extension study and were treated with a weekly 60 mg / kg bw intravenous dose of Respreeza for up to 24 months.
Slovenian: V podaljšek študije je bilo vključenih 140 preiskovancev (76 preiskovancev, ki so se v študiji RAPID zdravili z zdravilom Respreeza, in 64 preiskovancev, ki so prejemali placebo).
English: Powder for solution for infusion
Slovenian: prašek za raztopino za infundiranje
English: Posology The recommended dose of Respreeza is 60 mg / kg body weight (bw) administered once weekly.
Slovenian: Odmerjanje Priporočeni odmerek zdravila Respreeza je 60 mg/kg telesne mase, dan enkrat na teden.
English: Respreeza contains sodium
Slovenian: Zdravilo Respreeza vsebuje natrij
English: Powder and solvent for solution for infusion
Slovenian: prašek in vehikel za raztopino za infundiranje
English: • how to identify side effects, including signs of allergic reactions, and measures to be taken in case such effects occur (see also section 2 and section 4) Your doctor or your healthcare professional will regularly review your / your caregiver's infusion technique to ensure continued appropriate handling.
Slovenian: • kako identificirati neželene učinke, vključno z znaki alergijskih reakcij in ukrepi, ki jih je treba izvesti, če se pojavijo (glejte tudi poglavje 2 in poglavje 4).
English: Human alpha1-proteinase inhibitor 5,000 mg
Slovenian: humani zaviralec alfa1-proteinaze 5.000 mg
English: Human alpha1-proteinase inhibitor 4,000 mg
Slovenian: humani zaviralec alfa1-proteinaze 4.000 mg
English: Dizziness may occur after the administration of this medicine.
Slovenian: Po apliciranju tega zdravila se lahko pojavi omotica.
English: Human alpha1-proteinase inhibitor 1,000 mg
Slovenian: humani zaviralec alfa1-proteinaze 1.000 mg
English: Respreeza 5,000 mg powder and solvent for solution for infusion One vial contains approximately 5,000 mg of human alpha1-proteinase inhibitor*, as determined by its capacity to neutralize human neutrophil elastase.
Slovenian: Respreeza 5.000 mg prašek in vehikel za raztopino za infundiranje Ena viala vsebuje približno 5.000 mg humanega zaviralca alfa1-proteinaze*, kot je določeno glede na zmogljivost nevtralizacije humane nevtrofilne elastaze.
English: A double-blind, randomized, active-controlled, crossover pharmacokinetic study was conducted in 13 males and 5 females with alpha1-proteinase inhibitor deficiency, ranging in age from 36 to 66 years.
Slovenian: S 13 moškimi in 5 ženskami s pomanjkanjem zaviralca alfa1-proteinaze, starih od 36 do 66 let, so izvedli dvojno slepo, randomizirano, z učinkovino nadzorovano navzkrižno farmakokinetično študijo.
English: MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer of the biological active substance
Slovenian: Ime in naslov izdelovalca biološke učinkovine
English: Since human alpha1-proteinase inhibitor is an endogenous human protein, no adverse effects on fertility are expected when given at recommended doses.
Slovenian: Ker je humani zaviralec alfa1proteinaze endogena človeška beljakovina, ni verjetno, da bi v priporočenih odmerkih povzročili neželene učinke na plodnost.
English: Respreeza 4,000 mg powder and solvent for solution for infusion One vial contains approximately 4,000 mg of human alpha1-proteinase inhibitor*, as determined by its capacity to neutralize human neutrophil elastase.
Slovenian: Respreeza 4.000 mg prašek in vehikel za raztopino za infundiranje Ena viala vsebuje približno 4.000 mg humanega zaviralca alfa1-proteinaze*, kot je določeno glede na zmogljivost nevtralizacije humane nevtrofilne elastaze.
English: • Inspect the reconstituted solution for particulate matter and discoloration prior to administration.
Slovenian: • Pred dajanjem preverite rekonstituirano raztopino, da ne vsebuje delcev ali, da ni obarvana.
English: Respreeza 1,000 mg powder and solvent for solution for infusion One vial contains approximately 1,000 mg of human alpha1-proteinase inhibitor*, as determined by its capacity to neutralize human neutrophil elastase.
Slovenian: Respreeza 1.000 mg prašek in vehikel za raztopino za infundiranje Ena viala vsebuje približno 1.000 mg humanega zaviralca alfa1-proteinaze*, kot je določeno glede na zmogljivost nevtralizacije humane nevtrofilne elastaze.
English: After reconstitution with 95 ml solvent, the solution contains approximately 50 mg/ml of human alpha1-proteinase inhibitor.
Slovenian: Po rekonstituciji s 95 ml vehikla vsebuje raztopina približno 50 mg/ml humanega zaviralca alfa1-proteinaze.
English: Appropriate vaccination (hepatitis A and B) should be considered for patients in regular/repeated receipt of human plasma-derived proteinase inhibitors.
Slovenian: Pri bolnikih, ki redno/večkrat prejemajo zaviralce proteinaze, pridobljene iz človeške plazme, je treba razmisliti o ustreznem cepljenju (proti hepatitisu A in B).
English: After reconstitution with 76 ml solvent, the solution contains approximately 50 mg/ml of human alpha1-proteinase inhibitor.
Slovenian: Po rekonstituciji s 76 ml vehikla vsebuje raztopina približno 50 mg/ml humanega zaviralca alfa1-proteinaze.
English: Respreeza 1,000 mg powder and solvent for solution for infusion 3 years
Slovenian: Respreeza 1.000 mg prašek in vehikel za raztopino za infundiranje 3 leta
English: Respreeza 5,000 mg powder and solvent for solution for infusion 2 years
Slovenian: Respreeza 5.000 mg prašek in vehikel za raztopino za infundiranje 2 leti
English: Uncommon (≥1/1,000 to
Slovenian: Pogostnost neželenih učinkov pogosti (≥1/100 do občasni (≥1/1.000 do zelo redki neznana
English: Eye disorders
Slovenian: Očesne bolezni otekle oči
English: After reconstitution with 20 ml solvent, the solution contains approximately 50 mg/ml of human alpha1-proteinase inhibitor.
Slovenian: Po rekonstituciji z 20 ml vehikla vsebuje raztopina približno 50 mg/ml humanega zaviralca alfa1-proteinaze.
English: The MAH shall complete, within the stated timeframe, the below measures: Description
Slovenian: Imetnik dovoljenja za promet z zdravilom mora v določenem časovnem okviru izvesti naslednje ukrepe:
English: Follow steps below to remove entire Mix2Vial set from Respreeza vial:
Slovenian: Za odstranitev celotnega kompleta Mix2Vial iz viale z zdravilom Respreeza sledite spodnjim navodilom:
English: Respreeza 4,000 mg powder and solvent for solution for infusion 2 years
Slovenian: Respreeza 4.000 mg prašek in vehikel za raztopino za infundiranje 2 leti
English: Transmissible agents
Slovenian: Prenosljive snovi
English: What Respreeza contains
Slovenian: Kaj vsebuje navodilo
English: Respreeza 4,000 mg powder and solvent for solution for infusion Respreeza 4,000 mg of powder in a glass vial (type I), closed with a rubber (bromobutyl or chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Slovenian: Respreeza 4.000 mg prašek in vehikel za raztopino za infundiranje Zdravilo Respreeza 4.000 mg prašek v stekleni viali (tip I), zaprti z gumijastim (bromobutilnim ali klorobutilnim) zamaškom in aluminijasto folijo in plastično dvižno zaporko.
English: What Respreeza is
Slovenian: Kaj je zdravilo Respreeza
English: Respreeza 1,000 mg powder and solvent for solution for infusion Respreeza 1,000 mg of powder in a glass vial (type I), closed with a rubber (bromobutyl or chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Slovenian: Respreeza 1.000 mg prašek in vehikel za raztopino za infundiranje Zdravilo Respreeza 1.000 mg prašek v stekleni viali (tip I), zaprti z gumijastim (bromobutilnim ali klorobutilnim) zamaškom in aluminijasto folijo in plastično dvižno zaporko.
English: Respreeza 5,000 mg powder and solvent for solution for infusion Respreeza 5,000 mg of powder in a glass vial (type I), closed with a rubber (bromobutyl or chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Slovenian: Respreeza 5.000 mg prašek in vehikel za raztopino za infundiranje Zdravilo Respreeza 5.000 mg prašek v stekleni viali (tip I), zaprti z gumijastim (bromobutilnim ali klorobutilnim) zamaškom in aluminijasto folijo in plastično dvižno zaporko.
English: 95 ml of water for injections in a glass vial (type I), closed with a rubber (chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Slovenian: 95 ml vode za injekcije v stekleni viali (tip I), zaprti z gumijastim (klorobutilnim) zamaškom in aluminijasto folijo in plastično dvižno zaporko.
English: Consequences of an overdose are unknown.
Slovenian: Če ste uporabili večji odmerek zdravila Respreeza, kot bi smeli Posledice prevelikega odmerjanja niso znane.
English: 76 ml of water for injections in a glass vial (type I), closed with a rubber (chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Slovenian: 76 ml vode za injekcije v stekleni viali (tip I), zaprti z gumijastim (klorobutilnim) zamaškom in aluminijasto folijo in plastično dvižno zaporko.
English: Respreeza 5,000 mg powder and solvent for solution for infusion:
Slovenian: Respreeza 5.000 mg prašek in vehikel za raztopino za infundiranje:
English: Respreeza 1,000 mg powder and solvent for solution for infusion:
Slovenian: Respreeza 1.000 mg prašek in vehikel za raztopino za infundiranje:
English: Solvent for Respreeza
Slovenian: Vehikel za zdravilo Respreeza
English: Respreeza 4,000 mg powder and solvent for solution for infusion:
Slovenian: Respreeza 4.000 mg prašek in vehikel za raztopino za infundiranje:
English: 20 ml of water for injections in a glass vial (type I), closed with a rubber (chlorobutyl) stopper and an aluminium seal with a plastic flip off cap.
Slovenian: 20 ml vode za injekcije v stekleni viali (tip I), zaprti z gumijastim (klorobutilnim) zamaškom in aluminijasto folijo in plastično dvižno zaporko.
English: Reporting of side effects If you get any side effects, talk to your doctor or healthcare professional.
Slovenian: Če opazite katerega koli izmed neželenih učinkov, se posvetujte z zdravnikom ali zdravstvenim delavcem.
English: 1 solvent vial of 95 ml water for injections 1 transfer set 20/20 (Mix2Vial set) for reconstitution
Slovenian: 1 viala s praškom za enkratno uporabo 1 viala z vehiklom z 95 ml vode za injekcije 1 komplet za prenos 20/20 (komplet Mix2Vial) za rekonstitucijo
English: A healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency will supervise the first infusions.
Slovenian: Prvo infundiranje bo nadziral zdravstveni delavec z izkušnjami v zdravljenju pomanjkanja zaviralca alfa1-proteinaze.
English: 1 solvent vial of 76 ml water for injections 1 transfer set 20/20 (Mix2Vial set) for reconstitution
Slovenian: 1 viala s praškom za enkratno uporabo 1 viala z vehiklom z 76 ml vode za injekcije 1 komplet za prenos 20/20 (komplet Mix2Vial) za rekonstitucijo
English: 1 solvent vial of 20 ml water for injections 1 transfer set 20/20 (Mix2Vial set) for reconstitution
Slovenian: 1 viala s praškom za enkratno uporabo 1 viala z vehiklom z 20 ml vode za injekcije 1 komplet za prenos 20/20 (komplet Mix2Vial) za rekonstitucijo
English: Patients with renal or hepatic impairment
Slovenian: Žilne bolezni vročinski oblivi
English: Talk to your doctor or healthcare professional before using Respreeza.
Slovenian: Pred začetkom uporabe zdravila Respreeza se posvetujtez zdravnikom ali zdravstvenim delavcem.
English: Respreeza 5,000 mg powder for solution for infusion Human alpha1-proteinase inhibitor
Slovenian: Respreeza 5.000 mg prašek za raztopino za infundiranje humani zaviralec alfa1-proteinaze
English: Respreeza 1,000 mg powder for solution for infusion Human alpha1-proteinase inhibitor
Slovenian: Respreeza 1.000 mg prašek za raztopino za infundiranje humani zaviralec alfa1-proteinaze
English: Respreeza 4,000 mg powder for solution for infusion Human alpha1-proteinase inhibitor
Slovenian: Respreeza 4.000 mg prašek za raztopino za infundiranje humani zaviralec alfa1-proteinaze
English: Respreeza 5,000 mg powder and solvent for solution for infusion Human alpha1-proteinase inhibitor
Slovenian: Respreeza 5.000 mg prašek in vehikel za raztopino za infundiranje humani zaviralec alfa1-proteinaze
English: Respreeza 4,000 mg powder and solvent for solution for infusion Human alpha1-proteinase inhibitor
Slovenian: Respreeza 4.000 mg prašek in vehikel za raztopino za infundiranje humani zaviralec alfa1-proteinaze
English: One solvent vial of 95°ml water for injections One transfer set 20/20 (Mix2Vial set) for reconstitution
Slovenian: Respreeza 5.000 mg prašek in vehikel za raztopino za infundiranje: ena viala s praškom za enkratno uporabo ena viala z vehiklom z 95 ml vode za injekcije en komplet za prenos 20/20 (komplet Mix2vial) za rekonstitucijo
English: Respreeza 1,000 mg powder and solvent for solution for infusion Human alpha1-proteinase inhibitor
Slovenian: Respreeza 1.000 mg prašek in vehikel za raztopino za infundiranje humani zaviralec alfa1-proteinaze
English: This summary was last updated in July 2010.
Slovenian: Povzetek je bil nazadnje posodobljen 07-2010.
English: Pigs and horses should not be slaughtered for 5 days.
Slovenian: Prašičev in konjev se ne sme klati 5 dni.
English: Accidental self-injection may cause pain.
Slovenian: Nenamerno samoinjiciranje lahko povzroči bolečino.
English: They usually occur during the first week of treatment and tend to be temporary.
Slovenian: Najpogosteje se pojavijo v prvem tednu zdravljenja in so večinoma prehodni.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) MELOXIDYL EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) MELOXIDYL Povzetek EPAR za javnost
English: The European Commission granted a marketing authorisation valid throughout the European Union for Meloxidyl to Ceva Santé Animal on 15 January 2007.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Meloxidyl, veljavno po vsej Evropski uniji, odobrila družbi Ceva Santé Animal dne 15. januarja 2007.
English: Other information about Meloxidyl:
Slovenian: Druge informacije o zdravilu Meloxidyl:
English: After the last administration of Meloxidyl cattle should not be slaughtered for 15 days and the milk not used for 5 days.
Slovenian: Govedo, ki je prejelo zdravilo Meloxidyl, se ne sme klati 15 dni, mleko goveda pa se ne sme uporabljati 5 dni po zadnjem odmerku.
English: It can be used for both acute (sudden) disorders, such as those seen after an injury, and chronic (long-term) disorders.
Slovenian: Uporablja se lahko za akutne (nenadne) bolezni, npr. po poškodbi, ali kronične (dolgotrajne) bolezni.
English: A temporary swelling at the injection site can occur but resolves without intervention.
Slovenian: Lahko se pojavi prehodna oteklina na mestu injiciranja, vendar izzveni brez ukrepanja.
English: The Committee recommended that Meloxidyl should be given a marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Meloxidyl odobri dovoljenje za promet.
English: They include loss of appetite, vomiting, diarrhoea, blood in the stools and apathy (lack of vitality).
Slovenian: Med njimi so izguba teka, bruhanje, driska, kri v blatu in apatija (pomanjkanje vitalnosti).
English: In horses, anaphlylactoid (hypersensitivity) reactions can occur and should be treated symptomatically.
Slovenian: Pri konjih se lahko pojavijo anafilaktoidne (preobčutljivostne) reakcije, ki jih je treba zdraviti simptomatsko.
English: Meloxidyl is a pale green oral suspension (1.5 mg/ml) for dogs and (0.5 mg/ml) for cats, which is mixed into the food, and a yellow solution for injection (5 mg/ml) for dogs and cats as well as solution for injection (20 mg/ml) for cattle, pigs and horses.
Slovenian: Zdravilo Meloxidyl je svetlo zelena peroralna suspenzija (1,5 mg/ml) za pse in (0,5 mg/ml) mačke, ki se daje vmešana v hrano, rumena raztopina za injiciranje (5 mg/ml) za pse in mačke ter raztopina za injiciranje (20 mg/ml) za govedo, prašiče in konje.
English: Meloxidyl is a ‘generic': this means that Meloxidyl is similar to a ‘reference veterinary medicinal product' already authorised in the EU (Metacam).
Slovenian: Zdravilo Meloxidyl je „generično“ zdravilo, kar pomeni, da je podobno „referenčnemu veterinarskemu zdravilu“, ki je že odobreno v EU (zdravilu Metacam).
English: What benefit has Meloxidyl shown during the studies?
Slovenian: Kakšne koristi je zdravilo Meloxidyl izkazalo med študijami?
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that, in accordance with EU requirements, Meloxidyl has been shown to be bioequivalent to Metacam.
Slovenian: Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da je bilo v skladu z zahtevami Evropske unije dokazano, da je zdravilo Meloxidyl biološko enakovredno zdravilu Metacam.
English: If this happens, seek medical advice immediately and show the package leaflet or the label to the doctor.
Slovenian: Če se to zgodi, je treba nemudoma poiskati zdravniško pomoč in zdravniku pokazati navodilo za uporabo ali nalepko na ovojnini.
English: Because of this, Meloxidyl's benefit is taken as being the same as that of the reference medicinal product.
Slovenian: Zaradi tega velja, da so koristi zdravila Meloxidyl enake kot pri referenčnem zdravilu.
English: People who are hypersensitive to NSAIDs should avoid contact with Meloxidyl.
Slovenian: Osebe, ki so preobčutljive za (alergične na) NSPVZ, naj se izogibajo stiku z zdravilom Meloxidyl.
English: What is the risk associated with Meloxidyl?
Slovenian: Kakšna tveganja so povezana z zdravilom Meloxidyl?
English: Meloxidyl contains meloxicam, which belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
Slovenian: Zdravilo Meloxidyl vsebuje meloksikam, ki spada v skupino zdravil, imenovanih nesteroidna protivnetna zdravila (NSPVZ).
English: Studies have been carried out to prove that Meloxidyl is ‘bioequivalent' to the reference veterinary medicinal product: this means that Meloxidyl is equivalent to Metacam in the way it is absorbed and used by the body.
Slovenian: Študije so pokazale, da je zdravilo Meloxidyl „biološko enakovredno“ referenčnemu veterinarskemu zdravilu, kar pomeni, da je glede tega, kako ga telo absorbira in uporabi, enakovredno zdravilu Metacam.
English: If someone swallows the medicinal product, the advice of a doctor should be sought immediately.
Slovenian: Če ste zdravilo pogoltnili, se takoj posvetujte z zdravnikom.
English: Meloxidyl is a medicinal product that contains the active substance meloxicam.
Slovenian: Meloxidyl je zdravilo, ki vsebuje zdravilno učinkovino meloksikam.
English: As the prostaglandins are substances that trigger inflammation, pain, exudation and fever, meloxicam reduces those responses.
Slovenian: Ker prostaglandini sprožajo vnetje, bolečino, nabiranje tekočine in zvišano telesno temperaturo, meloksikam zmanjša obseg teh odzivov.
English: Therefore the CVMP's view was that, as for Metacam, Meloxidyl's benefits are greater than its risks.
Slovenian: Zato CVMP meni, da so koristi zdravila Meloxidyl, tako kot pri zdravilu Metacam, večje od z njim povezanih tveganj.
English: A study looked at how Meloxidyl was absorbed and its effects in the body, in comparison with Metacam.
Slovenian: V študiji so proučevali, kako se zdravilo Meloxidyl v primerjavi z zdravilom Metacam absorbira in deluje v telesu.
English: Based on the findings of the study, Meloxidyl was considered to be bioequivalent to the reference medicinal product.
Slovenian: Na podlagi izsledkov študije je bilo ugotovljeno, da je zdravilo Meloxidyl biološko enakovredno referenčnemu zdravilu.
English: Why has Meloxidyl been approved?
Slovenian: Zakaj je bilo zdravilo Melodixyl odobreno?
English: In cattle Meloxidyl injection is used to reduce clinical signs in case of acute respiratory infection with appropriate antibiotic therapy, to reduce clinical signs in case of diarrhoea in combination with oral re-hydration therapy in calves over one week of age and young, nonlactating cattle and as supportive therapy in the treatment of acute mastitis, in combination with antibiotics.
Slovenian: Pri govedu se injekcije zdravila Meloxidyl uporabljajo za zmanjšanje kliničnih znakov pri akutni okužbi dihal skupaj z ustreznim antibiotičnim zdravljenjem, za zmanjšanje kliničnih znakov pri driski v kombinaciji s peroralnim rehidracijskim zdravljenjem pri teletih, starejših od enega tedna, in mladem govedu, ki se ne doji, ter kot podporno zdravljenje pri zdravljenju akutnega mastitisa v kombinaciji z antibiotiki.
English: In dogs and cats the side effects seen with Meloxidyl are similar to those seen with other NSAIDs and occur only occasionally.
Slovenian: Neželeni učinki, opaženi pri zdravilu Meloxidyl so podobni tistim, opaženim pri drugih NSPVZ, pojavljajo pa se redko.
English: In pigs Meloxidyl injection is used to reduce the symptoms of lameness and inflammation in non-infectious locomotor disorders and for supportive therapy in the treatment of puerperal septicaemia and toxaemia around farrowing (mastitis-metritis-agalactia syndrome) with appropriate antibiotics.
Slovenian: Pri prašičih se injekcije zdravila Meloxidyl uporabljajo za zmanjšanje simptomov šepavosti in vnetij pri neinfekcijskih boleznih gibal ter za podporno zdravljenje pri zdravljenju puerperalne septikemije in toksemije ob oprasitvi (sindrom mastitis-metritis-agalakcija) skupaj z ustreznim antibiotičnim zdravljenjem.
English: In dogs, Meloxidyl is used as an oral suspension to relieve inflammation and pain in musculoskeletal disorders.
Slovenian: Pri psih se zdravilo Meloxidyl uporablja kot peroralna suspenzija za lajšanje vnetja in bolečin pri kostno-mišičnih obolenjih.
English: What is Meloxidyl used for?
Slovenian: Za kaj se zdravilo Meloxidyl uporablja?
English: How has Meloxidyl been studied?
Slovenian: Kako je bilo zdravilo Meloxidyl raziskano?
English: In horses Meloxidyl injection is used to relieve inflammation and pain in both acute and chronic musculo-skeletal disorders and for the relief of pain associated with colic.
Slovenian: Pri konjih se injekcije zdravila Meloxidyl uporabljajo za lajšanje vnetij in bolečin pri akutnih in kroničnih kostno-mišičnih obolenjih ter za zmanjšanje bolečin pri koliki.
English: In cats, Meloxidyl is used as an oral suspension to relieve inflammation and pain in chronic musculo-skeletal disorders as well as to relieve mild to moderate pain after an operation, such as spaying or soft tissue surgery.
Slovenian: Pri mačkah se zdravilo Meloxidyl kot peroralna suspenzija uporablja za lajšanje vnetij in pri kroničnih kostno-mišičnih obolenjih ter za lajšanje blagih do zmernih bolečin po operaciji skopljenja ali manjši operaciji mehkega tkiva.
English: How does Meloxidyl work?
Slovenian: Kako zdravilo Meloxidyl deluje?
English: As an injection, Meloxidyl is also used to reduce the pain and inflammation after an operation, such as orthopaedic or soft tissue surgery.
Slovenian: V obliki injekcije se zdravilo Meloxidyl uporablja tudi za zmanjševanje bolečine in vnetij po ortopedski operaciji ali operaciji mehkega tkiva.
English: What is Meloxidyl?
Slovenian: Kaj je zdravilo Meloxidyl?
English: Meloxidyl injection is used in cats to reduce the pain after an operation, such as spaying or minor soft tissue surgery.
Slovenian: Injekcija zdravila Meloxidyl se pri mačkah uporablja za lajšanje bolečin po operaciji sklopljenja ali manjši operaciji mehkega tkiva.